Experimental cancer combo shows promise but trial halted early

NCT ID NCT04972110

Terminated Disease control Sponsor: Repare Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a new drug, RP-3500 (camonsertib), combined with existing PARP inhibitors (niraparib or olaparib) in 156 adults with advanced solid tumors that have specific genetic markers. The goal was to find safe doses and see if the combination could shrink tumors. However, the study was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RP-3500 (camonsertib) combined with niraparib or olaparib
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced cancers that have specific genetic changes and have stopped responding to standard therapies.
What could go wrong: The trial was terminated early, so results are limited. The combination may cause significant side effects, and it is unclear if it will work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR, ADULT

Contacts and locations

Locations

Participating Site # 1001

Houston, Texas, 77030, United States
Participating Site # 1008

New York, New York, 10032, United States
Participating Site # 1013

Salt Lake City, Utah, 84112, United States
Participating Site # 1016

Rochester, Minnesota, 55905, United States
Participating Site #1009

Baltimore, Maryland, 21205, United States
Participating Site #1012

New Haven, Connecticut, 06511, United States
Participating Site #1015

Ann Arbor, Michigan, 48109, United States
Participating Site #1017

Jacksonville, Florida, 32224, United States
Participating Site #1018

Phoenix, Arizona, 97401, United States
Participating Site #1025

San Francisco, California, 94158, United States
Participating Site #1026

New York, New York, 10029, United States
Participating Site #1028

Aurora, Colorado, 80012, United States
Participating Site #1029

Eugene, Oregon, 97401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.